首页
外语
计算机
考研
公务员
职业资格
财经
工程
司法
医学
专升本
自考
实用职业技能
登录
外语
Even as pharmaceutical companies poured a record amount of money into drug development in 2005, the industry’s research drought
Even as pharmaceutical companies poured a record amount of money into drug development in 2005, the industry’s research drought
admin
2017-03-15
77
问题
Even as pharmaceutical companies poured a record amount of money into drug development in 2005, the industry’s research drought grew worse. According to newly released statistics from the Food and Drug Administration (FDA), it approved only 20 new drugs, down from 36 in 2004. Only once in last 10 years has the number of newly approved drugs been lower than last year’s figure.
The dry spell in 2005 came even as spending on research by the industry reached a new high, passing $38 billion. And in a rarity, several major companies failed to win approval for a new drug invented in their own labs, including Pfizer, Eli Lilly and Johnson & Johnson.
The decline in drug development came as scientists in and outside the companies were making great strides in genomics and other sorts of basic research into the way diseases develop, opening many potential new targets for treatment. Yet such progress in the laboratory has not translated so far into many new drugs on the market.
Some analysts say that the drug industry is in a cyclical trough, and that the number of new drugs—not just new applications for drugs already on the market—will start rising within a few years as research investments begin to pay off. But the FDA and the companies seem to agree that the process for testing and developing new drugs needs improvement.
"Our concern is that the development process itself is not keeping up at a fast enough pace to match the progress on the discovery end," said Dr. Scott Gottlieb, the agency’s deputy commissioner for medical and scientific affairs.
The FDA is looking for ways to speed the approval of new treatments—like approving drugs based on "surrogate endpoints," whether, for example, a cancer drug causes tumors to shrink instead of whether it prolongs the life of patients. It was on such a basis that the FDA last month approved Nexavar, a Bayer drug for treating kidney cancer.
But like finding new treatments, diagnosing the problem of drug development is easier than figuring out a solution. Even as the FDA looks for ways to speed the testing of new treatments, members of Congress and some consumer groups are calling for even more testing before drugs are approved.
The low output from research last year was even worse than the top-line figures might indicate. In 2004, important cancer treatments including Avastin, by Genentech, and Tarceva, through a partnership of Genentech and OSI Pharmaceuticals, were among the therapies that regulators allowed onto the market. The drugs that were approved were mostly for rare diseases like chronic iron overload, a condition for which the Novartis medicine Exjade received clearance.
In the meantime, the agency delayed approval of prominent new treatments like Pargluva, a diabetes drug from Bristol-Myers Squibb and Merck, and Exubera, a form of inhaled insulin from Pfizer.
The paucity of new products is a big reason that the stock prices of large drug makers have tended to fare poorly in recent years. Shares of Pfizer, the industry leader, for example, reached a peak of $49 in July 2000 and have trended downward since, closing yesterday at $24.44.
The drought in new drugs has led some industry executives to complain that the FDA is denying approval to good new treatments because of the criticism the agency has faced from lawmakers over Vioxx. Merck stopped selling its arthritis painkiller Vioxx in 2004 after a clinical trial showed that it increased the risks of heart attacks and strokes in patients taking it for 18 months or longer. Some other studies found heart attack risks as early as 2000, and the FDA has been criticized for not forcing Merck to withdraw the drug earlier or to warn doctors prominently of such risks.
Researching and developing a drug is a long and arduous process. Genentech’s work leading to Avastin, for example, began in 1989—15 years before the drug’s approval. Scientists first identify the cellular process of disease within the body. They may search for proteins that cancerous tumors release in order to spread, or receptors on the surface of a cell that become the targets of viruses.
The drug company then searches for chemical compounds or proteins that are able to interact with the targets the scientists have found—without damaging cells in other parts of the body. If a treatment appears to have therapeutic effects in test-tube and animal trials, the companies then move on to Phase I human testing, when a handful of healthy volunteers are given the therapy to make sure that it is safe enough for wider testing. In Phase II testing, the drug is tried on a few dozen to a few hundred patients for safety and effectiveness.
Finally, in Phase III development, the drug is tested in large-scale trials with as many as several thousand patients to demonstrate its effectiveness and to search for rarer side effects.
If the treatment is shown to be unsafe or ineffective at any stage, it fails development and is put aside.
According to a report in December from Merrill Lynch, the number of potential new drugs in Phase I and II testing has nearly doubled in the last decade, to 1,971 in 2004 from 1,010 in 1995. But that has not translated into success in Phase III development; the number of drugs in Phase III has been flat at fewer than 400.
"R&D statistics over the past decade have been disappointing," Merrill’s analysts wrote in their report. Still, the analysts predicted that companies would continue to increase research spending and expand their pipelines of early-stage drugs.
According to the author, the possible reasons for the dry spell of pharmaceutical companies lie in all the following EXCEPT (that)______.
选项
A、the paucity of investment companies made in research
B、the drug industry had trended downward and currently reached its low point
C、the development process did not match the pace of the related researches
D、FDA postponed the approval of prominent new medications in 2004
答案
A
解析
转载请注明原文地址:https://kaotiyun.com/show/FCSO777K
本试题收录于:
NAETI高级口译笔试题库外语翻译证书(NAETI)分类
0
NAETI高级口译笔试
外语翻译证书(NAETI)
相关试题推荐
VisitorstoBritainmayfindthebestplacetosamplelocalcultureisinatraditionalpub.Butthesefriendlyhostelriescanb
Modernindustrialsocietygrantslittlestatustooldpeople.Infact,suchasocietyhasasystemofbuilt-inobsolescence.The
AsurveyofcorporateAmericabyBusinessWeekshowedwhatthemagazinecalled"yawningdividebetweenfamily-friendlinessinth
Aftertheretirementhisparentsbeganto________asmallgrocerystore.
Shecoversdeadbodiessothattheydonotseebychildrencominghomefromschool.
Seekingtoframehisnewadministrationasonewithafirmfocusonclosingthegapbetweenchildrenfromaffluentandpoorfami
我国金融改革的不断深化将为外资银行与中资银行的合作带来新的机遇。银监会鼓励外资银行通过参股中资银行,在业务、客户和市场方面获得突破;同时,在公司治理、内控、风险管理和经营理念方面带来先进的经验和做法,使中、外资银行在合作中共同获得发展。作为深化金
A、Huntingandprotection.B、Chasingprey.C、Herdinglivestock.D、Keepingaccompany.D最初驯养狗的目的那部分内容比较有难度。原文用较快的语速回顾猜测了种种目的。现代人较为熟
几千年来,人类一直忙于制造工具和机器以减轻工作负担,自动化是机器代替人过程的最新发展阶段。自动化与宇宙飞船一样属于先进技术,但是与其相关的一些想法已有将近200年的历史了。1784年发明的蒸汽发动机是机械自动化控制最早的例子之一。二战期间,美国科学家发明了
Coca-Colahasbeenoperatinginternationallyformostofits100yearhistory.Todaythecompanyhasoperationsin160countries
随机试题
建设工程项目的总进度目标指的是整个项目的进度目标,它是在()阶段项目定义时确定的。
4岁女孩,因发热、头痛3天,昏迷、抽搐1天,于7月12日入院。查体:T40.5℃,深昏迷,双侧瞳孔缩小,呼吸40次/分,不规则,有时呈双吸气或抽泣样,频繁抽搐,肌张力增强,膝反射亢进,病理征阳性,脑膜刺激征阳性。外周血常规:WBC15×109/L,中性粒细
A.轻度刺激痛B.剧烈自发痛C.牵涉性痛D.持续性钝痛E.咬合痛带状疱疹的主要自觉症状是
百分吸收系数的物理意义是
下列关于个人信用贷款的贷款对象,说法正确的有()。
甲、乙、丙三人共同投资设立一合伙企业,合伙企业在存续期间,甲擅自以合伙企业的名义与丁公司签订了代销合同。乙和丙获知后,认为该合同不符合合伙企业利益,即向丁公司表示对该合同不予承认,因为该合伙企业内部规定,任何合伙人不得单独与第三人签订代销合同。对此,下列说
已知市场证券组合(marketportfolio)的预期回报为0.12,无风险利率为0.05,市场证券组合的标准差为0.1。用下列数据计算:[对外经济贸易大学2011研]计算由A、B构成的投资组合的β。
把内存中的数据保存到硬盘上的操作称为
下列说法中,正确的是
ThefaceoftheMoonischangedbycollisionswithmeteoroids,______newcraterstoappear.
最新回复
(
0
)